By Colin Kellaher
Beam Therapeutics has hired Sravan Emany as the biotechnology company's next chief financial officer.
Beam on Friday said Emany, who joins the Cambridge, Mass., company on Dec. 19, was most recently served as chief financial and operating officer at Ironwood Pharmaceuticals, which announced his pending departure late Wednesday.
Beam said Emany, 47 years old, will receive an annual base salary of $575,000, a sign-on bonus of $325,000 and an annual incentive bonus with a target of 50% of his base pay.
Beam earlier this year said its previous chief financial officer, Terry-Ann Burrell, was leaving to join JPMorgan Chase.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 06, 2024 07:16 ET (12:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.